Novonesis reports 8% sales growth in first nine months of 2025

DENMARK – Novonesis has delivered 8% organic sales growth in the first nine months of 2025, with the Full-year outlook narrowed upwards to 7-8%, from 6-8% previously.

Strong broad-based organic sales growth of 8%, including the negative impact of exiting certain countries of 1 percentage point. Price contributed by 1 percentage point (Q3: ~1 percentage point).

Food & Health at 9% organic sales growth including the negative impact of exiting certain countries of 2 percentage points. Planetary Health at 8% organic sales growth.

Emerging Markets at 12% organic sales growth, Developed Markets at 6% organic sales growth (Q3: 4%).

Adjusted EBITDA margin at 37.3%, up by 130 bps (Q3: down by 30 bps). including significant currency headwinds. Adjusted net profit increased by 22%.

NIBD/EBITDA at 2.0x, and free cash flow before acquisitions at EUR 668.4 million (Q3: EUR 361.3 million).

Ester Baiget, President & CEO: “I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and in Emerging and Developed Markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model.

“Following a robust nine-months performance including favorable timing in the third quarter, we indicate mid-single-digit organic sales growth for the fourth quarter and lift the bottom end of the range now expecting 7-8% for the full year. We continue to execute on our strategic priorities, positioning us firmly to deliver on our 2030 targets.”

2025 outlook

Organic sales growth is now expected between 7-8%, including an indication of mid-single-digit growth in Q4 following favorable timing in Q3.

Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9%. The adjusted EBITDA margin is expected at the lower end of the 37-38% range, including significant currency headwinds.

Novonesis reports 8% organic sales growth in full year 2024

Recently, the company reported 8% organic sales growth in 2024, amounting to US$3987.91 billion, an increase of 60% compared to 2023.

Emerging markets grew by 12% organically, and developed markets increased by 7%.

The gross margin was 47.2%. Excluding the PPA inventory step-up, depreciation, and amortisation, it was 56.8%, an increase from 54.3% in 2023.

The increase compared to 2023 was related to the lower cost of raw materials and logistics costs.

Subscribe to receive our email newsletters with the latest news and insights from Africa, the Middle East and around the world. SUBSCRIBE HERE